← All organizations
Highest phase reached
Phase 3
First clinical trial
Oct 1, 2000First marketed drug
Dec 20, 2017First NDA
Dec 20, 2017Last known activity
Sep 30, 2021
Timeline
1990s
- Jul 1, 1991
AEterna Zentaris— Founded
2000s
- Jun 5, 2009
Ardana Bioscience Ltd— Acquired
2010s
- Dec 20, 2017
macimorelin— Marketing Organization
- Dec 20, 2017
macimorelin— NDA Organization
2020s
- Dec 14, 2023
Ceapro Inc.— Acquired
Drugs by trial phase (27 distinct, 45 trials)
Phase 3 (12 own, 1 via acquisition)
Phase 2 (8 own, 1 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Approved for
Studied for
- Astrocytoma
- Brain Neoplasms
- Breast Neoplasms
- Cachexia
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Transitional Cell
- Chondrosarcoma
- Colonic Neoplasms
- Colorectal Neoplasms
- Dwarfism, Pituitary
- Endocrine System Diseases
- Endometrial Neoplasms
- Gastrointestinal Stromal Tumors
- Glioblastoma
- Glioma
- Hypertrophy
- Kidney Neoplasms
- Leishmaniasis
- Leishmaniasis, Cutaneous
- Leishmaniasis, Visceral
- Leukemia
- Lung Neoplasms
- Lymphoma
- Multiple Myeloma
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Plasma Cell
- Oligodendroglioma
- Ovarian Neoplasms
- Plasmacytoma
- Prostatic Hyperplasia
- Prostatic Neoplasms
- Sarcoma
- Sarcoma, Alveolar Soft Part
- Waldenstrom Macroglobulinemia
- Wasting Syndrome
Marketed drugs (1)
Subsidiaries (2 direct, 2 total across the full acquisition tree)
Recent trials (42)
- NCT04786873Lead sponsorPhase 3Sep 30, 2021
- NCT04786873Study directorPhase 3Sep 30, 2021
- NCT02558829Lead sponsorPhase 3Sep 1, 2015
- NCT02238496CollaboratorPhase 2Jul 1, 2014
- NCT01767155Lead sponsorPhase 3Apr 1, 2013
- NCT01698281Lead sponsorPhase 2Dec 1, 2012
- NCT01614990CollaboratorPhase 2May 1, 2012
- NCT01224730Lead sponsorPhase 1Jan 1, 2012
- NCT01240629CollaboratorPhase 1/Phase 2Nov 2, 2010
- NCT01234519Lead sponsorPhase 1/Phase 2Nov 1, 2010
- NCT01097018Lead sponsorPhase 3Apr 1, 2010
- NCT01049841CollaboratorPhase 1Jan 1, 2010
- NCT01002248Lead sponsorPhase 3Dec 1, 2009
- NCT01048580Lead sponsorPhase 1Oct 1, 2009
- NCT00776867CollaboratorPhase 1Oct 1, 2008
Details
- Founded
- Quebec, CA Jul 1, 1991
- First NDA
- Dec 20, 2017
- Last known activity
- Sep 30, 2021
Designations held
- Orphan drug